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Tau is a predominantly neuronal protein that is normally bound to microtubules, where it
acts to modulate neuronal and axonal stability. In humans, pathological forms of tau are
implicated in a range of diseases that are collectively known as tauopathies. Kinases and
phosphatases are responsible for maintaining the correct balance of tau phosphorylation
to enable axons to be both stable and labile enough to function properly. In the early
stages of tauopathies, this balance is interrupted leading to dissociation of tau from
microtubules. This leaves microtubules prone to damage and phosphorylated tau prone
to aggregation. Initially, phosphorylated tau forms oligomers, then fibrils, and ultimately
neurofibrillary tangles (NFTs). It is widely accepted that the initial soluble oligomeric forms
of tau are probably the most pathologically relevant species but there is relatively little
quantitative information to explain exactly what their toxic effects are at the individual
neuron level. Electrophysiology provides a valuable tool to help uncover the mechanisms
of action of tau oligomers on synaptic transmission within single neurons. Understanding
the concentration-, time-, and neuronal compartment-dependent actions of soluble tau
oligomers on neuronal and synaptic properties are essential to understanding how best
to counteract its effects and to develop effective treatment strategies. Here, we briefly
discuss the standard approaches used to elucidate these actions, focusing on the
advantages and shortcomings of the experimental procedures. Subsequently, we will
describe a new approach that addresses specific challenges with the current methods,
thus allowing real-time toxicity evaluation at the single-neuron level.
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INTRODUCTION
Structure and Physiological Functions of Tau
Tau is encoded by the microtubule-associated protein tau (MAPT) gene. As a monomer, it
is intrinsically disordered and lacks a significant secondary structure (Cleveland et al., 1977;
Barghorn et al., 2004; Mukrasch et al., 2009; Mirbaha et al., 2018). Tau associates with microtubules
and is key tomaintaining cellular and axonal morphology as well as assisting in vesicle transport and
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trafficking (Drechsel et al., 1992; Brandt and Lee, 1993; Brandt
et al., 1995; Tracy and Gan, 2018; Figure 1A). Tau binds to the
labile domain of microtubules to modulate their stabilization
and maintain free movement (Qiang et al., 2018). There are six
isoforms of tau in the adult human brain, which are differentially
expressed during development (Goedert et al., 1988, 1989;
Goedert and Jakes, 2005). The acidic N-terminal region can have
up to two inserts between amino acids 45 and 103 (generating 0N,
1N or 2N tau). Themid-region is rich in prolines, as well as serine
and threonine residues, the phosphorylation of which have been
linked to both physiological and pathophysiological processes
(Stoothoff and Johnson, 2005; Hanger et al., 2007; Hampel et al.,
2010; Wang et al., 2013). Towards the C-terminus, there are four
pseudo-repeat domains (R1-R4), referred to as the microtubule-
binding domains.
Tau can regulate axonal transport (Figure 1A), maintaining
protein trafficking both from the axon to the soma (retrograde;
Dixit et al., 2008) and from the soma to the axon (anterograde;
Stamer et al., 2002). Tau acts as a competitor for dynein
and kinesin binding sites on microtubules. It can also directly
modulate kinesin binding via its N-terminus (Kanaan et al.,
2011) or alter dynein binding by interactions with dynactin
(Magnani et al., 2007). Although most tau is localized in
axons, tau also plays a physiological role in dendrites, assisting
with spine remodeling which is required for synaptic plasticity
(Frandemiche et al., 2014; Regan et al., 2015; Figure 1A). Finally,
tau has reported roles in the nucleus in human neuroblastoma
cells, regulating the integrity of genomic DNA (Loomis et al.,
1990; Figure 1A).
Pathological Cascade Leading to Tangles
Tau function is modulated by post-translational modifications
such as phosphorylation, acetylation, and ubiquitination
(Beharry et al., 2014; Alonso et al., 2016). Finely regulated
levels of phosphorylation (by kinases and phosphatases;
Figure 1B) on specific residues contribute to the protein’s
physiological functions (Stoothoff and Johnson, 2005). In disease
states, regulation of the balance between phosphorylation
and de-phosphorylation is lost, leading to increased
abnormal (‘‘hyper’’) phosphorylation (Köpke et al., 1993).
Hyperphosphorylated tau dissociates frommicrotubules and can
sequester normal tau away from tubulin, disrupting microtubule
function, and stability (Qiang et al., 2018). Aggregation-
incompetent monomeric tau protein (Mirbaha et al., 2018)
undergoes monomer-monomer interactions via disulfide
bonding or hexapeptide motifs to drive a conformational change
from an unfolded, disordered structure to a new structured
conformation that is rich in beta-sheets and aggregation-
competent (Friedhoff et al., 1998; Congdon et al., 2008). This
marks the beginning of the pathological cascade starting with
the aggregation to oligomeric structures, through to fibrils
and then to neurofibrillary tangles (NFTs; Avila et al., 2006;
Maeda et al., 2006; Figure 1C). NFTs were assumed to be
the toxic species since their presence is characteristic of brain
tau pathology (Braak and Braak, 1991). However, soluble tau
oligomers formed much earlier in the aggregation process may
be the primary drivers of toxicity (Lee et al., 2001; Wittman
et al., 2001; Tanemura et al., 2002; Tatebayashi et al., 2002;
Andorfer et al., 2003; Spires et al., 2006; Yoshiyama et al.,
2007; Cowan et al., 2010). Reports that some toxic forms
of tau with specific pathological mutations aggregate into
oligomers but do not form fibrils further support this theory
(Lasagna-Reeves et al., 2010, 2014; Karikari et al., 2019a).
In cell culture experiments, tau oligomers applied to media
were taken up into the nuclei of human neuroblastoma cells
and stem cell-derived cortical neurons (Usenovic et al., 2015;
Wegmann et al., 2016; Evans et al., 2018; Karikari et al., 2019a;
Puangmalai et al., 2020). In humans and transgenic mice
models, phospho-tau impairs nuclear transport by interacting
with the nuclear pore complex and disrupting its activities
(Eftekharzadeh et al., 2018). Toxic tau oligomers are transferred
between neurons by extracellular release, then uptake by
neighboring neurons where it induces the aggregation of
endogenous tau and possibly other proteins (Walsh and Selkoe,
2016; Gibbons et al., 2019). This process has been studied
extensively in cell and transgenic animal models (Clavaguera
et al., 2009; Guo and Lee, 2011; Iba et al., 2013; Boluda et al.,
2015; Usenovic et al., 2015; Wegmann et al., 2016; Narasimhan
et al., 2017; Evans et al., 2018; Karikari et al., 2019b; He et al.,
2020; Puangmalai et al., 2020) and is believed to be regulated
by the low-density lipoprotein receptor-related protein 1
(Rauch et al., 2020).
Primary and Secondary Tauopathies
Tauopathies represent a group of diseases in which neuronal
dysfunction and loss are primarily governed by the presence of
abnormal tau protein. Tauopathies have varying histopathology
and clinical presentations and can often be distinguished by
the isoforms and ultrastructure of the tau aggregates (Dickson
et al., 2011; Rademakers et al., 2012). Tauopathies can be
classified broadly by whether tau aggregates are the sole
primary pathological feature. The most common tauopathy,
Alzheimer’s disease (AD), is a secondary tauopathy due to
the presence of other contributory pathological factors such
as extracellular amyloid-beta plaques (Jack et al., 2013). The
presence of amyloid-beta aggregates and phosphorylated tau
aggregates (NFTs) are used for pathological confirmation of
AD diagnosis at post mortem (Guillozet et al., 2003). In the
human Alzheimer brain, tau aggregates spread stereotypically
following the pathological staging of tau pathology proposed
by Braak and Braak (Braak and Braak, 1991), as confirmed
recently by neuroimaging studies (Vogel et al., 2020).
Clinically, NFT accumulation is observed in the brains of
AD patients and correlates well with disease progression
(Wischik et al., 1988).
Tau also plays a role in mediating the pathogenesis of
other oligomeric proteins such as amyloid-beta (Castillo-
Carranza et al., 2015), alpha-synuclein (Castillo-Carranza
et al., 2018; Teravskis et al., 2018) and prion protein (Reiniger
et al., 2010; Corbett et al., 2020). One of the pioneering
approaches to prepare tau oligomers in vitro induced tau
aggregation with amyloid-beta or alpha-synuclein aggregates
(Lasagna-Reeves et al., 2010). Similarly, tau oligomers have been
shown to induce alpha-synuclein toxicity (Gerson et al., 2018).
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FIGURE 1 | Tau in physiology and pathophysiology. Tau has many physiological roles in neurons (A). (i) The most prominent function is in the modulation of
microtubule stability and assembly. (ii) Tau also plays a role in the nucleus, potentially regulating the integrity of genomic DNA by binding to different chromosomal
regions. (iii) The third role for tau in physiology is in the regulation of axonal transport by interfering with the binding of motor proteins kinesin and dynein to
microtubules, thus altering the movement of cellular materials between the soma and axon. (iv) Finally, tau is believed to play important roles in the regulation of
synaptic plasticity, for example by its contribution to the process of spine remodeling. Design concept from Wang and Mandelkow (2016). (B) Under physiological
conditions, tau is bound to microtubules. The stability of microtubules is maintained by the balanced activities of kinases and phosphatases acting to regulate the
binding of tau to the microtubules. (C) If the balance is altered in favor of increased kinase activity, then tau can become hyperphosphorylated and detach from the
microtubules affecting stability and tau aggregation. Initially, monomers aggregate to form oligomers which are β-sheet-rich and are thought to be the smallest toxic
species. Subsequently, these species aggregate further into protofibrils, fibrils, and finally into neurofibrillary tangles (NFTs). Created with BioRender.
Furthermore, Puzzo et al. (2017) described a common
mechanism for oligomeric amyloid-beta and tau toxicity
involving the binding of the amyloid precursor protein (APP).
The authors demonstrated APP-mediated defects in behavior
and synaptic plasticity following the tau oligomer application.
Oligomeric forms of tau are formed following mild traumatic
brain injury (Bittar et al., 2019). Together, these results suggest
that tau can act in concert with amyloid-beta (as shown in AD;
Skillbäck et al., 2015) and alpha-synuclein (as in some cases of
Parkinson’s disease; Goris et al., 2007 andMoussaud et al., 2014).
THE PATHOLOGICAL RELEVANCE OF
USING ELECTROPHYSIOLOGY TO MODEL
TAU FUNCTIONS IN PHYSIOLOGY AND
PATHOPHYSIOLOGY
Although the toxicity of tau oligomers has been studied
extensively histopathologically in human and animal models,
there is surprisingly little quantitative information describing
their direct effects on neurons. Different studies employ
a range of concentrations of tau oligomers, often higher
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than the physiological levels of the protein. Moreover, cells
and animals are treated with tau oligomers for variable
amounts of time. Consequently, it is unclear if cytotoxicity
is dependent on tau oligomer concentration and/or duration
of treatment. Since tau oligomers mediate cytotoxicity partly
by altering synaptic and electrophysiological properties, it
is important to document their concentration-, time- and
structure-dependent actions on neurons. Electrophysiological
techniques can provide direct measures of neuronal function
and highlight the direct implications of aggregated tau
for circuit function. The majority of studies have been
carried out using in vitro rodent models. Recording
from acutely isolated brain slices is a highly effective
method as it allows much greater control, in terms of tau
concentration and pharmacological manipulation than in vivo
measurements, while retaining the cell architecture and local
synaptic morphology.
Electrophysiological Techniques: A Brief
Overview
Here, we briefly introduce two commonly used in vitro
electrophysiological techniques that enable the study of tau
oligomer-mediated effects on neuronal function. Recording
extracellular field responses allows an overview at the
circuit level and permits the understanding of local network
dysfunction following the bath perfusion of oligomers or
in transgenic models. Given that tau oligomers can disrupt
synaptic transmission and plasticity, this is a valuable tool
to evaluate effects on connectivity. Field recordings in the
hippocampus are most commonly performed by stimulating the
Schaffer collateral fibers and recording excitatory postsynaptic
potentials (EPSPs) in the CA1 region where they make synapses
onto pyramidal cells (Figure 2A). Details of how to perform
extracellular field recordings are outlined by Zhang et al. (2014).
Field recordings are useful as they sample many synapses and
thus provide an average response. They can also be used to
record action potential firing when the circuit is activated by
excitant solutions.
The second technique permits a more targeted approach and
the evaluation of effects at a single neuron level. The whole-cell
patch-clamp recording is a well-established technique (originally
developed by Neher and Sakmann, 1976), whereby a high
resistance seal is formed between the tip of the recording pipette
and the membrane of the target cell. Additional negative pressure
ruptures the membrane (termed whole-cell breakthrough) and
the contents of the patch pipette dialyze into the target neuron
whilst allowing simultaneous current and voltage measurements
from the recorded cell (Figure 2B). Details of how to perform
whole-cell patch-clamp are discussed in VanHook and Thoreson
(2014). This method provides high-resolution measurements
from single neurons including sub-threshold information (such
as changes in membrane potential and input resistance) which is
not obtainable from extracellular field recordings. This method
can be used with various tau delivery approaches, including
transgenic models, extracellular bath perfusion, or delivery via
the patch pipette.
Conventional Methods to Study Pathology:
Lessons and Limitations
Transgenic Models
A classic approach to study physiological tau function is to
generate transgenic mouse models, for example by the genetic
manipulation of theMAPT gene. This has been done in a variety
of transgenic lines with phenotypic effects being compared with
wild-type littermates. These approaches have greatly furthered
our understanding of tau, however, there are limitations.
Germline knockouts can result in compensation from other
microtubule-associated proteins, which can complicate the
interpretation of the data. For example, in MAPT−/− mouse
models there are limited functional effects, as other axonal
proteins such as microtubule-associated protein 1A (MAP1A)
can compensate to perform the microtubule-stabilization
functions of tau (Harada et al., 1994; Dawson et al., 2001; Tucker
et al., 2001; Fujio et al., 2007).
Most transgenic lines for the study of AD work by promoting
either the aggregation or overexpression of tau, amyloid-beta (or
its parent molecule, the APP) or a combination to replicate the
protein species implicated in disease pathology. Overexpression
of human tau in rodent models can result in synaptic and
behavioral dysfunction as well as the neuronal loss (Andorfer
et al., 2005; Polydoro et al., 2009), mediated by smaller
aggregates including oligomers (Lee et al., 2001; Tanemura
et al., 2002; Tatebayashi et al., 2002; Wittman et al., 2001;
Andorfer et al., 2003; Spires et al., 2006; Yoshiyama et al., 2007;
Cowan et al., 2010). A challenge with using electrophysiology
to study overexpression lines is that whilst specific observations
may be associated with the presence or absence of NFTs and
other defined late-stage aggregates, they cannot provide an
understanding of the exact form(s) of tau that is responsible. This
introduces variation into the electrophysiology data and makes
equating changes in neuronal properties with tau aggregate
structure and concentration difficult.
Even in transgenic animals that are believed to preferably
accumulate soluble tau oligomers, an opportunity to study
the toxic potentials of oligomers of different sizes and forms
would be highly valuable in answering several outstanding
questions, including: (i) which forms of tau oligomers mediate
most of the toxicity?; (ii) is aggregation the mediator of tau
electrophysiological toxicity?; (iii) how does the presence of tau
oligomers in an individual neuron affect its synaptic connections
with neighboring neurons? and (iv) are these effects pre- or post-
synaptic? In these transgenic models, it is presently not possible
to quantify the form(s) of tau oligomers present within each
recorded cell, limiting direct analysis of disease-relevant toxicity.
Extracellular Application to Culture Models
or to in vitro Slices
Another approach is to deliver oligomeric tau to in vitro brain
slices by perfusion or to inject them in vivo. These studies
describe tau-mediated synaptic, mitochondrial, and memory
impairments (Lasagna-Reeves et al., 2012; Fá et al., 2016;
Ondrejcak et al., 2018; Acquarone et al., 2019). An advantage
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FIGURE 2 | Electrophysiological approaches to measuring neuronal function. A brief overview of the common electrophysiological approaches used to evaluate tau
oligomer function. in vivo experiments give the greatest level of translatability to the research as the whole brain remains intact. However, in vitro experiments permit
much greater control over oligomer concentration and pharmacological manipulation. (A) A schematic illustration to demonstrate extracellular field recording in the
CA1 region of the hippocampus. A stimulating electrode is placed in the Schaffer collateral fiber region and a recording electrode in the CA1 region where they
synapse onto pyramidal cells, to record excitatory postsynaptic potentials (EPSPs). This technique allows for the study of local circuit activity. (B) The whole-cell
patch-clamp allows for the parameterization of neuronal function on a single-cell level. By forming a high resistance seal between the pipette and the membrane of
the target cell, then breaking through (with negative pressure), the contents of the patch pipette will dialyze into the cell. (i) This technique can be used to deliver
proteins and peptides of known concentration and defined structure directly into target cells whilst simultaneously making current and voltage measurements in a
network that is free from pathology. (ii) The whole-cell patch-clamp permits the study of tau mislocalization, with fluorescently labeled tau diffusing to synaptic
structures above the dendritic bifurcation. Tau oligomers can be targeted to pre or postsynaptic neurons during multiple whole-cell recordings. (iii) An example where
3 layer V pyramidal cells were simultaneously recorded. The neuron on the left has tau oligomers introduced from the patch pipette whereas the other two cells
receive a vehicle. (iv) Example traces from presynaptic neurons (tau oligomer) showing action potential firing pattern to induce EPSPs in postsynaptic neurons
(vehicle). Created in part with BioRender. Reproduced in part using content previously published in Hill et al. (2019); eNeuro on a CC-BY 4.0 license.
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of this approach over transgenic models is that these methods
can facilitate both the study of recombinant preparations of
tau oligomers and of tau oligomer preparations that have
been isolated from human brains, for example from patients
suffering from tau pathology (Lasagna-Reeves et al., 2012). This
enhances the translatability of findings. One limitation is that
the observed effects cannot be attributed to tau oligomers being
intracellular, as the applied proteins may be acting extracellularly
or indirectly through other cells, such as glia and astrocytes.
It is also unclear how much oligomeric tau has been taken up
into neurons, which may vary considerably from cell to cell.
Although in vivo studies provide the advantage of applying tau
oligomers within a living system, any effects observed cannot be
attributed to specific forms or concentrations of tau oligomers.
A protocol that can assess tau oligomer effects on neuronal
function in a structurally- and concentration-defined manner
would greatly assist in clarifying the outstanding questions
listed above.
Pathologically Relevant Functions of Tau
Oligomers Identified Using
Electrophysiology
Electrophysiological measurements have uncovered several
pathophysiological mechanisms mediated by tau oligomers,
including altering the intrinsic excitability of pyramidal neurons
and modulating both short- and long-term plasticity (Hoover
et al., 2010; Rocher et al., 2010; Lasagna-Reeves et al., 2012;
Puzzo et al., 2017; Tamagnini et al., 2017; Mondragón-
Rodríguez et al., 2018). In recent years, several new pathological
roles for tau have been described—particularly regarding its
ability to induce synaptic dysfunction. Zhou et al. (2017)
suggest that this occurs as a result of tau mis-localizing to
the presynaptic terminals and binding to synaptic vesicles.
Through actin crosslinking, it reduces their motility resulting
in reduced release rate. This is a clear pre-synaptic mechanism
of dysfunction, but post-synaptic mechanisms have also been
reported. For example, administrating intracerebroventricular
injections of tau oligomers that were isolated from AD
patient brains inhibited long-term potentiation (LTP), a form
of synaptic plasticity thought to underlie memory formation
(Ondrejcak et al., 2018).
A NEW APPROACH TO STUDYING
OLIGOMERIC TAU PATHOLOGY
Given the limitations of previous approaches, Kaufmann et al.
(2016) described an approach utilizing structurally defined,
concentration-controlled preparations of oligomers. Here, alpha-
synuclein aggregates were introduced through the patch-pipette
during whole-cell patch-clamp recording from cortical neurons
in vitro, and the subsequent electrophysiological changes
measured. This approach has since been implemented by other
groups to study alpha-synuclein pathology (Wu et al., 2019) and
has been extended by Hill et al. (2019) to examine tau oligomers.
The authors demonstrated that oligomeric tau (prepared as
described in Karikari et al., 2017, 2019a) can induce significant
changes to action potential dynamics, disrupt basal synaptic
transmission and inhibit synaptic plasticity on a 40-min time
scale (Hill et al., 2019; Figure 2B) despite the concentration
being significantly lower (44–666 nM) than the physiological
concentration of tau (2 µM in neurons, Avila, 2010). Tau
oligomers diffused from the site of introduction (soma) to
synaptic sites during the 40-min recording (Hill et al., 2019).
At presynaptic sites, tau oligomers induced the run-down of
unitary excitatory postsynaptic potentials (EPSPs), which was
associated with increased short-term depression. In contrast, the
introduction of tau oligomers into postsynaptic neurons did
not affect basal synaptic transmission but markedly impaired
the induction of LTP (Hill et al., 2019). The introduction
of equivalent concentrations of tau monomers did not affect
neuronal or synaptic properties.
This single-neuron approach avoids a number of the
limitations of previous electrophysiological approaches. It allows
one cell to be targeted in a neural network that is free
from tau pathology, allowing direct time- and concentration-
dependent effects of tau oligomers to be measured. The amount
of tau required for the experiments is small and if labeled,
the introduced tau oligomers can be tracked within the cell
(Figure 2B). Upon whole-cell breakthrough, each cell acts as its
control, and changes to electrophysiological parameters can be
monitored over time from this baseline. Tau oligomers can be
targeted into pre- or postsynaptic cells so that separate effects
on synaptic transmission or plasticity can be uncovered. This
provides an unparalleled level of mechanistic detail.
DISCUSSION
Tau plays an indisputable role in several primary and secondary
tauopathies, therefore anti-tau immunotherapy is an attractive
target to slow down the progression or treat these diseases.
Immunotherapies will target different epitopes of tau and
therefore will alter its function in different ways. It is likely that,
if immunotherapy is successful for one tauopathy, that same one
form of immunotherapy may likely not be sufficient to work
across all tauopathies and so a targeted approach will be needed
(Sigurdsson, 2018). For example, ‘‘Gosuranemab’’ (Biogen, 2019)
was unsuccessful at phase 2 for patients with progressive
supranuclear palsy but is also now being tested in a phase
2 trial in AD. Basic science underpins the understanding of the
mechanisms of tau mediated degeneration. This needs to guide
the development of potential treatment strategies, to facilitate
their timely success. Traditional electrophysiological approaches
have described pathophysiological roles for oligomeric tau at
synapses, particularly in disrupting synaptic transmission and
plasticity (Lasagna-Reeves et al., 2012; Fá et al., 2016; Puzzo et al.,
2017; Ondrejcak et al., 2018). Direct introduction into neurons
has provided further detail into the different sites of action for
the oligomers at pre- and post-synapses. It has also allowed the
evaluation of the earliest changes to cellular electrophysiological
properties (Hill et al., 2019). The remaining questions lie in
further understanding of how tau oligomers are mediating these
changes. Once this is known, better-targeted treatments can be
developed. The earlier the stage of pathology that treatment can
be initiated, the greater chance of success.
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